<DOC>
	<DOCNO>NCT00976599</DOCNO>
	<brief_summary>To explore effect CP-690,550 blood synovial marker subject rheumatoid arthritis . To evaluate safety , tolerability efficacy CP-690,550 .</brief_summary>
	<brief_title>A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subject must diagnosis rheumatoid arthritis base American College Rheumatology Association The subject active disease Screening Baseline , define : ≥4 joint tender painful motion , AND ≥4 joint swell ; The subject must least one knee , one elbow , one wrist two metacarpophalangeal joint active synovitis suitable biopsy shaver technique No arthroscopy perform past 3 month joint biopsied study . No intraarticular steroid inject joint biopsied study previous 3 month . Subjects evidence hematopoietic disorder evidence hemoglobin level &lt; 9.0 gm/dL hematocrit &lt; 30 % screen visit within 3 month prior baseline synovial biopsy . An absolute white blood cell ( WBC ) count &lt; 3.0 x 109/L ( &lt; 3000/mm3 ) absolute neutrophil count &lt; 1.2 X 109/L ( &lt; 1200/mm3 ) screen visit within 3 month prior baseline synovial biopsy . Thrombocytopenia , define platelet count &lt; 100 x 109/L ( &lt; 100,000/mm3 ) screen visit within 3 month prior baseline synovial biopsy . Estimated GFR le 40 ml/min base Cockcroft Gault calculation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>